Fig. 2
From: Adoptive cell therapy using PD-1+ myeloma-reactive T cells eliminates established myeloma in mice
![Fig. 2](http://media.springernature.com/full/springer-static/image/art%3A10.1186%2Fs40425-017-0256-z/MediaObjects/40425_2017_256_Fig2_HTML.gif)
PD-1+ T cells from myeloma-bearing mice are phenotypically heterogeneous and secrete effector cytokines. KaLwRij mice were inoculated with 2 × 106 5T33-GFP cells iv. Spleens were harvested 28 days later for analysis. a Flow cytometric analysis of PD-1 co-expression with inhibitory receptors TIM-3 and LAG-3, and activation markers CD69, CD137, OX-40 and CD103 on CD8+ and CD4+ T cells. b Percentages of PD-1+Foxp3+CD4+ T cells analyzed by flow cytometry. c T cells were activated with 1 μg/ml plate bound anti-CD3 and anti-CD28 for 6 h, and analyzed for the presence of intracellular cytokines by flow cytometry. d Multiplex cytokine analysis of culture supernatants from T cells activated with 5 μg/ml plate bound anti-CD3 (clone 2C11) for 48 h. Data shown are representative of more than four independent analyses. *p ≤ 0.05, **p ≤ 0.01 and ***p ≤ 0.001